We are a clinical-stage nanomedicine platform company developing ACCURINS®, a new class of targeted and programmable therapeutics developed using our MEDICINAL NANOENGINEERING® platform. ACCURINS® are nanoparticles designed with specified physical and chemical characteristics to target specific cells or tissues and concentrate a therapeutic payload at the site of disease, enhancing efficacy while minimizing adverse effects on healthy tissues. We are developing our own pipeline of ACCURINS®, initially in oncology, as well as ACCURINS® in collaboration with biopharmaceutical companies.
We are evaluating next steps for our most clinically advanced ACCURIN drug candidate, BIND-014, which has completed enrolling patients in two phase 2 trials: iNSITE1 in squamous histology non-small cell lung cancer (NSCLC) and iNSITE 2 in advanced cervical and head and neck cancers. The company has announced ongoing collaborations with Pfizer Inc., AstraZeneca AB, F. Hoffmann-La Roche Ltd., Merck & Co., or Merck (known as Merck Sharp & Dohme outside the United States and Canada), Macrophage Therapeutics (a subsidiary of Navidea Biopharmaceuticals), Synergy Pharmaceuticals and PeptiDream, Inc. to develop ACCURINS® based on their proprietary therapeutic payloads and/or targeting ligands. BIND's collaboration with AstraZeneca has resulted in the Aurora B Kinase inhibitor Accurin AZD2811, which became the second Accurin candidate to enter clinical development. BIND's collaboration with Pfizer has resulted in the selection of an Accurin candidate that is in IND-enabling activity.
View all » Recent Releases
View all »Events & Presentations
May 9, 2016 at 8:30 AM ET
BIND Therapeutics First Quarter 2016 Financial Results